LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

About Study 19

TFST

Lynparza treatment compared to placebo
Lynparza treatment compared to placebo

For patients with BRCA mutation, Lynparza delays the need for subsequent treatment.4, 35

In patients with a BRCA mutation, Lynparza delayed the time from randomisation to start of first subsequent therapy or death (TFST)††, or when patients needed their next chemotherapy, by a median of 9.4 months (HR 0.32; 95% CI 0.22-0.48; p<0.0001; median 15.6 months vs 6.2 months).35

A comparison chart between Placebo and Lynparza about TSFT
A comparison chart between Placebo and Lynparza about TSFT

Adapted with permission from Ledermann.35

††An exploratory retrospective analysis.